查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1572093

注意力不足过动症市场：按治疗方法、患者类型和应用分类 - 全球预测 2025-2030

Attention Deficit Hyperactivity Disorder Market by Therapies (Pharmacotherapy, Psychotherapy), Patient Type (In-Patients, Out-Patients), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

注意力不足过动症市场2023年估值为149.9亿美元，预计2024年将达到156.1亿美元，复合年增长率为4.18%，到2030年将达到199.8亿美元，预计将达到1000万美元。

注意力不足过动症(ADHD) 是一种神经发育障碍，其特征是注意力不集中、过动和衝动，影响儿童的教育表现和成人的职业生产力。 ADHD 市场分析的范围包括药物、行为疗法和数位疗法，其驱动因素包括意识的提高、诊断程序的改善和盛行率的增加。 ADHD治疗的需要和应用是基于改善患者的生活质量，这对家庭、教育机构和职场都具有重要意义。最终用途范围包括儿科和成人患者、教育机构、医疗保健提供者、实验室等。该市场的驱动因素包括不断增加的发病率、复杂的治疗选择以及社会对心理健康需求的认识不断增强。关键的成长要素包括远端医疗服务、个人化医疗和政府医疗保健倡议等技术进步。机会包括越来越多地接受数位疗法和非侵入性神经反馈疗法等新型疗法。鼓励市场相关人员投资这些新技术的研发，扩大与医疗机构和学术机构的合作关係，并推广产品。儘管成长轨迹充满活力，但挑战仍然存在，包括污名化、地区不同的诊断标准以及高昂的治疗成本。进一步的障碍包括新药认证的监管障碍以及扩大保险覆盖范围的复杂性。需要开拓创新领域，包括人工智慧驱动的诊断工具、具有成本效益的治疗提供模式以及消除耻辱感的宣传活动。 ADHD 市场本质上是动态的，由医疗保健、技术和社会文化趋势的相互作用形成。透过投资以患者为中心的创新和策略伙伴关係关係而定位于这些领域融合的公司可能会在这一领域取得成功。为了有效捕捉市场潜力，企业必须保持适应能力，以快速回应不断变化的监管标准和消费者期望。

主要市场统计
基准年[2023] 149.9亿美元
预测年份 [2024] 156.1亿美元
预测年份 [2030] 199.8亿美元
复合年增长率（%） 4.18%

市场动态：针对快速发展的注意力不足过动症市场揭示的关键市场洞察

供需的动态交互作用正在改变注意力不足过动症市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球儿童和成人注意力不足过动症的盛行率不断上升
    • 早期发现注意力不足过动症的诊断工具和技术的进展
    • 提高家长和教育工作者对注意力不足过动症的认识和教育倡议
    • 注意力不足过动症市场创新治疗方法的研发活动迅速增加
  • 市场限制因素
    • 由于缺乏具有多动症专业知识的合格心理健康专业人员，造成诊断和治疗的延迟和错误
  • 市场机会
    • 针对不同年龄层过动症患者症状特异性缓解的创新药物製剂
    • 客製化的教育计画和工具旨在增强过动症儿童的学习体验
    • 针对患有多动症的成年人的职场适应解决方案着重于提高生产力和心理健康
  • 市场挑战
    • ADHD 诊断和治疗的高昂费用和有限的保险覆盖范围降低了患者的可及性。

波特的五力：驾驭注意力不足过动症市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解注意力不足过动症市场的外在影响

外在宏观环境因素在塑造注意力不足过动症市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解注意力不足过动症市场的竞争格局

注意力不足过动症市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 在注意力不足过动症市场的定位矩阵供应商绩效评估

FPNV 定位矩阵是评估注意力不足过动症市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製注意力不足过动症市场的成功之路

对注意力不足过动症市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球儿童和成人注意力不足过动症盛行率上升
      • 早期发现注意力不足过动症的诊断工具和技术的进展
      • 家长和教育工作者对注意力不足过动症的认识和教育工作正在不断增加。
      • 注意力不足过动症市场创新治疗方法的研发活动激增
    • 抑制因素
      • 缺乏具有多动症专业知识的合格心理健康专业人员会导致诊断和治疗的延迟或治疗的不正确。
    • 机会
      • 针对不同年龄层 ADHD 症状特异性缓解的创新药物配方
      • 旨在改善过动症儿童的学习体验的客製化教育计划和工具
      • 针对成人的过动症职场调整解决方案，专注于提高生产力和心理健康
    • 任务
      • ADHD 诊断和治疗的高成本和有限的保险范围限制了患者的取得。
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章注意力不足过动症的市场疗法

  • 药物治疗
    • 无刺激性
    • 兴奋剂
  • 心理治疗
    • 行为疗法
    • 认知行为疗法
    • 家庭治疗
    • 社交技能训练

第 7 章依病患类型分類的注意力不足过动症市场

  • 住院病人
  • 门诊病人

第八章注意力不足过动症市场：依应用分类

  • 注意力缺陷障碍
  • 过动症

第九章美洲注意力不足过动症市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区注意力不足过动症市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲注意力不足过动症市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C0088

The Attention Deficit Hyperactivity Disorder Market was valued at USD 14.99 billion in 2023, expected to reach USD 15.61 billion in 2024, and is projected to grow at a CAGR of 4.18%, to USD 19.98 billion by 2030.

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity, impacting children's educational performance and adults' professional productivity. The scope of market analysis for ADHD encompasses pharmaceuticals, behavioral therapy, and digital therapies, driven by rising awareness, improved diagnostic procedures, and increased prevalence. The necessity and application of ADHD treatments are based on enhancing patients' life quality, making them crucial for households, educational institutions, and workplaces. The end-use scope includes pediatric and adult patients, educational settings, healthcare providers, and research labs. The market is propelled by increasing incidence rates, sophisticated treatment options, and heightened societal recognition of mental health needs. Key growth influencers include technological advancements like telehealth services, personalized medicine, and government healthcare initiatives. Opportunistically, the evolving acceptance of novel treatments like digital therapeutics and non-invasive neurofeedback therapies presents unexplored opportunities. Market players are recommended to invest in R&D for these emerging technologies and expand collaborations with healthcare facilities and academic institutions for broader product dissemination. Despite the vibrant growth trajectory, challenges such as stigmatization, varied diagnosis standards across regions, and high treatment costs persist. Additionally, regulatory hurdles for new drug approvals and the complexity of gaining widespread insurance coverage pose barriers. Innovation areas ripe for exploration include AI-driven diagnostic tools, cost-effective treatment delivery models, and awareness campaigns to battle stigma. The ADHD market is inherently dynamic, shaped by intersecting healthcare, technological, and sociocultural trends. Businesses positioning themselves at the convergence of these domains with investment in patient-centered innovations and strategic partnerships stand the best chance of thriving in this sector. Companies should maintain adaptability to swiftly align with evolving regulatory standards and consumer expectations to capture market potential effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 14.99 billion
Estimated Year [2024] USD 15.61 billion
Forecast Year [2030] USD 19.98 billion
CAGR (%) 4.18%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Attention Deficit Hyperactivity Disorder Market

The Attention Deficit Hyperactivity Disorder Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of attention deficit hyperactivity disorder among children and adults worldwide
    • Advancements in diagnostic tools and techniques for early detection of attention deficit hyperactivity disorder
    • Growing awareness and educational initiatives about attention deficit hyperactivity disorder among parents and educators
    • Surge in research and development activities for innovative treatment options in attention deficit hyperactivity disorder market
  • Market Restraints
    • Lack of qualified mental health professionals with expertise in ADHD leading to delayed or incorrect diagnosis and treatment
  • Market Opportunities
    • Innovative pharmaceutical formulations targeting symptom-specific relief for different age groups with ADHD
    • Customized educational programs and tools designed to enhance learning experiences for children with ADHD
    • Workplace accommodation solutions for adults with ADHD focusing on productivity and mental health improvement
  • Market Challenges
    • High cost of ADHD diagnosis and treatment combined with limited insurance coverage reduces accessibility for patients

Porter's Five Forces: A Strategic Tool for Navigating the Attention Deficit Hyperactivity Disorder Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Attention Deficit Hyperactivity Disorder Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Attention Deficit Hyperactivity Disorder Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Attention Deficit Hyperactivity Disorder Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Attention Deficit Hyperactivity Disorder Market

A detailed market share analysis in the Attention Deficit Hyperactivity Disorder Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Attention Deficit Hyperactivity Disorder Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Attention Deficit Hyperactivity Disorder Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Attention Deficit Hyperactivity Disorder Market

A strategic analysis of the Attention Deficit Hyperactivity Disorder Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Attention Deficit Hyperactivity Disorder Market, highlighting leading vendors and their innovative profiles. These include Akili Interactive Labs, Inc., Austedo Pharmaceuticals, Cingulate Therapeutics, LLC, Eli Lilly and Company, Ironshore Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., KemPharm, Inc., Medice Arzneimittel Putter GmbH & Co. KG, Neos Therapeutics, Inc., NeuroSigma, Inc., NLS Pharmaceutics AG, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Shire Plc, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Attention Deficit Hyperactivity Disorder Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapies, market is studied across Pharmacotherapy and Psychotherapy. The Pharmacotherapy is further studied across Non-Stimulants and Stimulants. The Psychotherapy is further studied across Behavioral Therapy, Cognitive Behavioral Therapy, Family Therapy, and Social Skills Training.
  • Based on Patient Type, market is studied across In-Patients and Out-Patients.
  • Based on Application, market is studied across Attention Deficit Disorder and Hyperactive Disorder.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of attention deficit hyperactivity disorder among children and adults worldwide
      • 5.1.1.2. Advancements in diagnostic tools and techniques for early detection of attention deficit hyperactivity disorder
      • 5.1.1.3. Growing awareness and educational initiatives about attention deficit hyperactivity disorder among parents and educators
      • 5.1.1.4. Surge in research and development activities for innovative treatment options in attention deficit hyperactivity disorder market
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of qualified mental health professionals with expertise in ADHD leading to delayed or incorrect diagnosis and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovative pharmaceutical formulations targeting symptom-specific relief for different age groups with ADHD
      • 5.1.3.2. Customized educational programs and tools designed to enhance learning experiences for children with ADHD
      • 5.1.3.3. Workplace accommodation solutions for adults with ADHD focusing on productivity and mental health improvement
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of ADHD diagnosis and treatment combined with limited insurance coverage reduces accessibility for patients
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Attention Deficit Hyperactivity Disorder Market, by Therapies

  • 6.1. Introduction
  • 6.2. Pharmacotherapy
    • 6.2.1. Non-Stimulants
    • 6.2.2. Stimulants
  • 6.3. Psychotherapy
    • 6.3.1. Behavioral Therapy
    • 6.3.2. Cognitive Behavioral Therapy
    • 6.3.3. Family Therapy
    • 6.3.4. Social Skills Training

7. Attention Deficit Hyperactivity Disorder Market, by Patient Type

  • 7.1. Introduction
  • 7.2. In-Patients
  • 7.3. Out-Patients

8. Attention Deficit Hyperactivity Disorder Market, by Application

  • 8.1. Introduction
  • 8.2. Attention Deficit Disorder
  • 8.3. Hyperactive Disorder

9. Americas Attention Deficit Hyperactivity Disorder Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Attention Deficit Hyperactivity Disorder Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Attention Deficit Hyperactivity Disorder Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Akili Interactive Labs, Inc.
  • 2. Austedo Pharmaceuticals
  • 3. Cingulate Therapeutics, LLC
  • 4. Eli Lilly and Company
  • 5. Ironshore Pharmaceuticals Inc.
  • 6. Janssen Pharmaceuticals, Inc.
  • 7. KemPharm, Inc.
  • 8. Medice Arzneimittel Putter GmbH & Co. KG
  • 9. Neos Therapeutics, Inc.
  • 10. NeuroSigma, Inc.
  • 11. NLS Pharmaceutics AG
  • 12. Novartis AG
  • 13. Otsuka Pharmaceutical Co., Ltd.
  • 14. Pfizer Inc.
  • 15. Shire Plc
  • 16. Sunovion Pharmaceuticals Inc.
  • 17. Supernus Pharmaceuticals, Inc.
  • 18. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET RESEARCH PROCESS
  • FIGURE 2. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET DYNAMICS
  • TABLE 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON-STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY SOCIAL SKILLS TRAINING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY IN-PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY OUT-PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ATTENTION DEFICIT DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HYPERACTIVE DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 234. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET, FPNV POSITIONING MATRIX, 2023